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Background: Delayed entry into HIV care has complicated the challenges faced in sub-Saharan Africa due to the
high HIV burden. A clear knowledge of the factors affecting delayed entry will be essential in directing interventions
towards reducing delayed entry into HIV care. There exist very limited data on delayed entry in Cameroon despite
its relevance; hence this study was conducted to determine the rate of delayed entry and its associated factors in
HIV programmes in Cameroon.
Methods: Data used for this study was routine data obtained from the files of HIV patients who were diagnosed
between January 1, 2015 and June 30, 2015 at Limbe and Buea regional hospital HIV centers in the South West
region of Cameroon. Data analysis was done using SPSS version 20.
Results: Of the 223 patients included in the study, nearly one-quarter of patients (22.4 %) delayed to enter HIV care
within 3 months. Those who delayed to enter care were less likely to present at first diagnosis (using HIV rapid test)
with symptoms such as fever > 1 month (5 % versus 30 %, p = 0.01) and weight loss > 10 % (13 % versus 48 %, p <
0.001). Alcohol consumption, WHO stage and CD4 count levels were also associated with delayed entry in bivariate
analysis. In multivariate analysis only CD4 count greater than 500cells/μl and WHO stages I and II were
independently associated with delayed entry into HIV care within 3 months.
Conclusion: In the South West region of Cameroon, approximately 1 out of 4 patients delay to enter HIV care. This
high proportion of patients who delay to enter care correlates to the findings recorded by other studies in sub Saharan
Africa. Interventions tackling delayed entry into HIV care might need to be favorably directed towards patients that
have high CD4 counts and are at very early WHO clinical stages.
Keywords: Delayed entry, Factors associatedBackground
The global burden of HIV is clearly unevenly distributed
with sub-Saharan Africa having the greatest share of the
spread and sequelae of the pandemic [1, 2]. With an
estimated 24.7 million people living with HIV in sub-
Saharan Africa, accounting for almost 71 % of the global
HIV burden, the region continues to face enormous* Correspondence: takahnoah@yahoo.com
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(http://creativecommons.org/publicdomain/zechallenges to control the spread of the pandemic as well
as to adequately and effectively managed old and newly
infected people living with HIV [3]. Despite the suc-
cesses registered so far in the domain of increasing ac-
cess to antiretroviral medications and curbing the spread
of new HIV infections, the effective tracking and moni-
toring of HIV infected patients still present as daunting
challenges that urgently need to be addressed for the
success of HIV care programmes in the sub-Saharan
Africa region [4–10].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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particular),the United States (US) President’s Emergency
Plan For AIDS Relief (PEPFAR) through the US Centres
for Disease Control and Prevention (CDC) have directed
substantial amounts of funds towards addressing the chal-
lenges faced by countries towards HIV diagnosis [11].
Through local implementing partners, the efforts of PEP-
FAR and the CDC have resulted in improved CD4 testing
that ensures the issuing of same day CD4 test results to
newly diagnosed HIV positive patients [12, 13]. Despite
these efforts, several studies in Africa have reported
delayed entry into HIV care and loss to follow up after ini-
tial HIV diagnosis [14–16]. Delayed entry into HIV care
has been defined by the World Health Organization [17]
and from several published studies as not having a CD4
measurement within 3 months of HIV diagnosis [18–20]. A
better understanding of the factors affecting delayed entry
before antiretroviral therapy initiation will be necessary in
guiding interventions towards ensuring timely CD4 meas-
urement and eventual enrolment into the HIV continuum
of care [21]. Despite the relevance of studies in delayed
entry into HIV care, there exist limited published data on
its epidemiology in Cameroon. This study was therefore
designed and conducted to determine the prevalence of
delayed entry into HIV care, the socio-demographic and
clinical profiles of patients newly diagnosed of HIV and the
factors that are associated with delayed entry into HIV care
in Cameroon.Methods
Study design and Area
This was a cross-sectional study conducted in the two
major HIV care and treatment centres in the South West
region of Cameroon namely the Buea Regional and Limbe
Regional Hospitals, from the 1st January 2015 to June 30th
2015. The hospitals selected cover more than two thirds of
the total HIV population in the South West region and are
well situated in the Regional Capital (Buea health district
with population = 133,092 inhabitants) and the Divisional
Capital (Limbe health district with population = 151,258
inhabitants) with relatively high population densities. Both
centres are equipped with the Alere PIMA CD4 point of
care diagnostic machines permitting the issuing of same
day CD4 results. Each of the centres receives averagely 20–
23 newly diagnosed HIV positive patients every month.Sample size and sampling technique
A convenience sampling technique was used. A total of
223 adult (≥18 years) non pregnant patients who pre-
sented at both centres and were newly diagnosed HIV
positive between January 1st 2015 to June 30th 2015 were
included in the study consecutively.Data collection and study procedure
Data used for this study was routine data obtained from
the files of HIV patients who were diagnosed between
January 1, 2015 and June 30, 2015 at Limbe and Buea
regional hospitals HIV centers in the South West region
of Cameroon. A structured data collection form was
developed by the research team following the flow of
HIV programme activities from patient identification,
consultation, pre-test counselling and testing and post-
test counselling in the two centres. The data collection
form consisted of socio-demographic characteristics, the
medical history of the patients, the clinical presentation
and WHO staging, the laboratory tests and the date
when HIV rapid test and CD4 test were done. The
socio-demographic characteristics included the age, sex,
religion (Christian, Muslim and others), marital status,
educational level, household size, sharing of results,
occupation, place of residence and time taken to reach
treatment centres. The educational level was classified
based on the level of study and/or certificates obtained.
The educational levels were classified into primary (if
elementary school was attended and/or first school living
certificate was obtained), secondary (if college was
attended and/or college certificates obtained) and uni-
versity education (if a school of higher learning was
attended and/or certificates obtained). The number of
family members in each household (household size) was
recorded. The time taken to reach the treatment centres
was classified into less than 1 h and greater than 1 h.
The data collection form also included questions on
whether the participants shared their results with close
family members (wife, children, siblings or parents) or
friends by showing the HIV test result to them. In the
medical history, presence of other associated chronic
diseases (Tuberculosis, diabetes, hypertension and hepa-
titis) and sexually transmitted infections was noted. Al-
cohol consumers were classified into low, moderate and
excessive alcohol consumers. Excessive alcohol con-
sumption was based on intake of either more than 3 (2
for women) standard glasses of wine per day or more
than 10 (5 for women) local beers (1 local beer contains
28 g of alcohol) per week. Moderate alcohol consumption
was based on intake of 25–30 g per day. The clinical symp-
toms and signs were noted for each patient by the nurses at
the treatment centre and this was used to classify the pa-
tients according to the World Health Organization (WHO)
staging [22]. The laboratory tests performed by the patients
were also collected and included HIV rapid tests (for HIV
½ and the time when test was performed), CD4 test (the
value and the time test was performed), hemoglobin and
full blood count. The drug history of the patients was also
noted.
After the administrative and ethical approvals had
been obtained, the investigators proceeded to complete
Table 1 Socio-demographic characteristics of the study
population (N = 223)
Characteristics Frequency/Mean ± SD Percentage
Age, Mean ± SD,
median(range)
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files of the patients that were initially filled by the nurses
at the care and treatment centres.
Definition of delayed entry
A patient was said to have delayed to enter HIV care if he/
she did not have a CD4 measurement within 3 months of
HIV diagnosis [18, 23].
Data analysis
Data were analyzed using the Statistical Package for
Social Sciences (SSPS Inc, Chicago, Illinois, USA) ver-
sion 20.0 software. Results are summarized as counts
and percentages for categorical variables and as mean
and standard deviation (SD) for quantitative variables.
Group comparison used the Student t-test for quanti-
tative variables and the chi-square test for categorical
variables. To assess the factors associated with delayed
entry, bivariate and multivariate logistic regression
models were used. A p-value 0.05 was considered sta-
tistically significant.
We controlled for confounding in the analysis by using a
multiple logistics regression through backward elimination
in which if a variable was suspected to be confounder, we
removed the variable from the model and checked if the
odds ratios and significance of the rest of the variables left
in the new model changed significantly. If removing a vari-
able from the model resulted in a significant change in the
odds ratios, they were maintained in the model even if they
were statistically insignificant.
Results
Clinical characteristics of the study population
In this study, the participants were between 18 and
65 years old with a median age of 32 years. 88 (39.5 %) of
the participants were between 21 and 30 years old, 140
(62.8 %) of the participants were females and 90 (43.7 %)
had primary education (Table 1). In addition, 178 (79.8 %)
shared their results with close family members (Table 2).
Prevalence of delayed entry into HIV care and its
associated factors
Our findings reveal that, nearly 1 out of 4 patients
(22.4 %) delayed to enter care within 3 months of initial
HIV diagnosis (Table 2). Those who delayed to enter
care were less likely to present for HIV rapid testing
with symptoms such as fever > 1 month (5 % versus
30 %, p = 0.01) and weight loss > 10 % (13 % versus 48 %,
p < 0.001) (Table 2). Alcohol consumption, WHO stage
and CD4 count levels were also associated with delayed
entry in bivariate analysis (Table 2 and Table 3). The
presence of symptoms such as fever and weight loss
seemed to be strong predictors of delayed entry (and
indirectly care seeking behaviour) but further analysisrevealed that they were confounded by the WHO stages
I and II. In multivariate analysis, only CD4 count greater
than 500cells/μl 3.6 (0.6 – 10.4, p = 0.012] and WHO
stages I and II 5.4 (1.9 – 15.2, p = 0.01] were independ-
ently associated with delayed entry into HIV care within
3 months (Table 3).
In the backward elimination method of adjustment for
confounders in the regression model, removal of the
variables such as age, gender and alcohol consumption
led to significant changes in the odds ratios of CD4 and
WHO stage. These variables were therefore maintained
in the model.
Discussion
Our study reveal that the proportion of those who de-
layed to enter HIV care was nearly 1 out of 4 patients.
This high proportion of delayed entry was driven by high
CD4 count at first diagnosis and early WHO clinical
stages (stages I and II).
The high percentage of those who delay to enter HIV
care observed in our study is comparable to many other
studies that have been carried out in other parts of the
Table 2 Characteristics of the study population according to delay entry status
Characteristics Total (N = 223) n(%) or mean ± SD Delayed (N = 50) n(%) or mean ± SD Not delayed (N = 173) n(%) or mean ± SD p-value
Age 33.3 ± 9.3 33.4 ± 11.3 33.3 ± 8.7 0.10
Gender
Male 83 (37.2) 19 (38.0) 64 (36.9) 0.10
Female 140 (62.8) 31 (62.0) 109 (63.1)
Result shared 178(79.8) 30(60.0) 148 (85.5) 0.92
Alcohol 121 (54.3) 34 (68.0) 87 (50.3) 0.04
WHO HIV stage
WHO I 125 (56.1) 20 (40.0) 105 (61.0) <0.001
WHO II 38 (17.0) 17 (34.0) 21 (12.0)
WHO III 54 (25.2) 10 (20.0) 44 (25.0)
WHO IV 06 (2) 3 (6.0) 04 (2.0)
Fever >1 month 35 (15.7) 5 (10.0) 30 (17.3) 0.010
Weight loss > 10 % 47 (21.1) 23 (13.3) 24 (48.0) <0.001
CD4 count 441.4 ± 279.3 458.2 ± 281.7 384.7 ± 266.2 0.01
Travel hours to TC 0.7 ± 1.4 0.7 ± 1.5 0.3 ± 0.6 0.082
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colleagues carried out a systematic review between test-
ing and treatment initiation in sub Saharan Africa and
demonstrated that the rate of delay entry between HIV
diagnosis and receipt of first CD4 measurement varies
between 12 % and 65 % [24]. The proportion of those
who delay to enter HIV care in our study is also quite
close to the 29.7 % reported by Alvarez-Uria and
colleagues [25] in India and 23.2 % reported by Jennes
and associates [20] in the United States. Delayed entry
into care therefore cuts across both developed and
developing settings of the World with its highest rate in
sub Saharan Africa. This similar rates of delayed entry
with non-African settings can be due to the similarity in
the patterns of factors associated with delay entry such
as refusal to accept HIV status in both African and non-
African settings [20]. The high percentage of those who
delay to enter HIV care in our setting can be linked to
the fact that in the early era of rapid antiretroviral treat-
ment (ART) scale up, much attention was directed
towards initiating eligible patients on ART while those
who were HIV positive and not eligible (that is those in
the pre-HAART period) were not given enough atten-
tion and follow up [24]. Furthermore, the rate of delayed
entry can be even higher if a single group of patients is
put under investigation [26].
Several studies in Africa have attempted to investigate
the factors associated with the phenomenon of delayed
entry into HIV care [14, 21, 25, 27]. In our study, we
investigated if factors such age, gender, educational level,
alcohol consumption, travel hours from the treatment
centres, sharing of results with a family member or
friend,anemia,CD4 count on first diagnosis and WHOclinical staging were associated with delayed entry.
From our study, high CD4 (greater than 500cells/μl)
and WHO stages I and II were strongly associated with
delay entry. While many studies have reported this
positive relationship between high CD4 and delayed
entry [15, 18, 25, 28] some other studies in Guinea-
Bissau and Uganda have reported an association
between low CD4 count and delayed entry [9, 29]. The
relationship between high CD4 count and delay entry
may be related to the observation that most of such
patients feel healthy or asymptomatic (WHO stage I)
[18, 29], and they may tend to think they still have
some time before development of symptoms or they
may live in denial, refusing to accept their HIV status.
Even though our study showed that age was not
significantly associated with delayed entry, there exist
some evidence from other studies that young age is
significantly associated with other factors which may
be related to delayed entry into care such as accept-
ance of HIV positive status and initiation on lifelong
antiretroviral therapy tend to be problematic among
young HIV patients [30, 31].
Using a convenient sample and a cross sectional study
design poses some limitations. Importantly, a cross
sectional study design can only describe temporal rela-
tionships between factors observed and the outcome
irrespective of the strength of the associations observed,
and therefore only provides plausible hypotheses that
can be explored using other study designs [32]. Variables
such as sharing of results may change over time as par-
ticipants receive appropriate post-test counselling. This
could not be captured by a cross sectional study design.
Using a consecutive sample in a hospital setting means
Table 3 Factors associated with delay entry into HIV care within
3 months; Logistics regression analysis
Characteristics Bivariate analysis Multivariate analysis
OR (95%CI) p-value OR (95%CI) p-value
Age
>32 years Ref
≤32 years 1.5 (0.8 – 3.1) 0.10 2.8 (0.6 – 2.3) 0.18
Gender
Female Ref
Male 3.5 (1.3 – 9.2) 0.10 1.2 (0.8 – 5.5) 0.22
Educational level
Higher Ref
Nil 2.1 (0.3 – 13.8) 0.45
Primary 1.7 (0.4 – 8.1) 0.51
Secondary 0.5 (0.1 – 3.0) 0.43
Alcohol
No Ref
Yes 2.7 (1.9 – 7.9) 0.04 1.5 (0.5 – 4.8) 0.47
Anaemia
Hb≤ 9 g/dL Ref
Hb > 9 g/dL 2.6 (0.2 - 30.2) 0.43
CD4count
<499cells/μl Ref
≥500cells/μl 4.9 (1.4 – 17.5) 0.01 3.6 (0.6 – 10.4) 0.012
Travel hours to TC
≤1 h Ref
>1 h 1.2 (0.3 – 4.5) 0.75
WHO-HIV stage
WHO III&IV Ref
WHO I & II 6.1 (2.3 – 16.2) <0.001 5.4 (1.9 – 15.2) 0.01
Sharing of result
No Ref
Yes 1.2 (0.7 – 3.4) 0.92
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representative of the population of HIV positive patients
in Cameroon. This warrants further multicenter studies
which also include individuals diagnosed in non-hospital
settings such as community outreach. Using routine data
captured in the files of patients led to some missing data
on alcohol consumption. The quality of data collected
on variables such as alcohol consumption would have
been much better if face to face interviews were
conducted. Due to this limitation in the quality of data
collected on alcohol consumption, the association with
delayed entry into HIV care should be interpreted with
caution. However, in our setting where diagnosis of HIV
is still associated with a substantial level of stigma, face
to face interviews would have markedly resulted in a lowresponse rate and small sample size for the study. In
terms of the representativeness of our sample, since we
included all HIV patients diagnosed within the period of
study in the two main centres responsible for HIV care
in the South West region of Cameroon, our sample
could be representative of patients diagnosed within
health care settings in this region of the country. With
regards to data collection, despite the missing data on
alcohol consumption, we encountered very little chal-
lenges on the quality of data collected on other variables
because we ensured that the nurses that were in-charge
of filling in and coding patient files were all trained on
quality of data recording. Furthermore, it is necessary to
also note that this study is the first of its kind in the sub-
ject of delayed entry in Cameroon and in an era of
greater emphasis on testing, treating, tracking and follow
up of HIV patients, its relevance cannot be overempha-
sized. Our findings provide some key information that
would guide interventions to address delayed entry into
HIV care after diagnosis by suggesting the group of
newly diagnosed HIV patients to be suitably targeted in
our setting; with the goal of reducing cascade losses at a
key point in the HIV care continuum. Consequently, a
larger multicenter cohort study is urgently needed to
fine tune our observations made so far by establishing
with a higher degree of certainty the predictors of
delayed entry in our setting.
Conclusion
In the South West region of Cameroon, approximately 1
out of 4 patients delay to enter HIV care. This high pro-
portion of patients who delay to enter care correlates to
the findings recorded by other studies in sub Saharan
Africa. Interventions tackling delay entry into HIV care
might need to be favorably directed towards patients that
have high CD4 counts and are at very early WHO clinical
stages.
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